Zoetis Inc. (NYSE:ZTS) is one of the best drug stocks to buy right now. Zoetis Inc. (NYSE:ZTS) announced on September 12 the adoption of a positive opinion by the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) regarding recommending the granting of marketing authorization for Portela (relfovetmab). Is Zoetis a Unique Dividend Play in the Pharma Space for 2025? Portela is a new monoclonal antibody (mAb) therapy intended to alleviate pain associated with osteoarth ...

Key Takeaways Zoetis gained CVMP support for Portela, a monoclonal antibody for feline OA pain relief.Portela offers up to 3 months of pain relief with one jab and was well-tolerated in clinical studies.Portela will complement Solensia, giving vets and owners both monthly and quarterly OA pain therapy options.Zoetis (ZTS) announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) has issued a positive opinion for its investigational monoclonal antibody (mAb) therapy, P ...